98%
921
2 minutes
20
Introduction: The need for transesophageal echocardiography (TEE) before catheter ablation of atrial fibrillation (CA-AF) is still being questioned. The aim of this study is to analyze patients' (patients) risk factors of left atrial appendage thrombus (LAAT) prior to CA-AF in daily clinical practice, according to oral anticoagulation (OAC) strategies recommended by current guidelines.
Methods And Results: All patients scheduled for CA-AF from 01/2015 to 12/2016 in our center were included and either treated with NOACs (novel-OAC; paused 24-hours preablation) or continuous vitamin K antagonists (INR 2.0-3.0). All patients received a preprocedural TEE at the day of ablation. Two groups were defined: (1) patients without LAAT, (2) patients with LAAT. The incidence of LAAT was 0.78% (13 of 1,658 patients). No LAAT was detected in patients with a CHA DS -VASc score of ≤1 (n = 640 patients) irrespective of the underlying AF type. Independent predictors for LAAT are: higher CHA DS -VASc scores (odds ratio [OR] 1.54, 95%-confidence interval [CI]: 1.07-2.23, P = 0.0019), a history of nonparoxysmal AF (OR 7.96, 95%-CI: 1.52-146.64, P = 0.049), hypertrophic cardiomyopathy (HCM; OR 9.63, 95% CI: 1.36-43.05, P = 0.007), and a left ventricular ejection fraction (LVEF) < 30% (OR 8.32, 95% CI: 1.18-36.29, P = 0.011). The type of OAC was not predictive (P = 0.70).
Conclusions: The incidence of LAAT in patients scheduled for CA-AF is low. Therefore, periprocedural OAC strategies recommended by current guidelines seem feasible. Preprocedural TEE may be dispensed in patients with a CHA DS -VASc score ≤1. However, a CHA DS -VASc score ≥2, reduced LVEF, HCM, or history of nonparoxysmal AF are independently associated with an increased risk for LAAT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jce.13279 | DOI Listing |
Heart Rhythm O2
August 2025
Hospital Privado del Sur & Hospital Regional Español, Bahía Blanca, Argentina.
Background: Patient characteristics and outcomes of newly diagnosed atrial fibrillation (AF) have been investigated in large registries.
Objective: The study aimed to address the role of non-invasive screening tools in diagnosing AF in the Argentinian clinical practice.
Methods: This was an observational retrospective study.
Neurologia (Engl Ed)
September 2025
Hospital Universitario de Salamanca, CIBERCV, IBSAL, Spain.
Background: Oral anticoagulation (OAC) use increases the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) and CHADS-VASc ≥2. Left atrial appendage occlusion (LAAO) is an alternative to OAC, however data about its use in patients with prior ICH is scarce and the timing of its performance is controversial. Furthermore, the long-term outcomes in this group of patients have not been described previously.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Cardiology Division, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
Aims: Patients with acute coronary syndrome (ACS) may experience adverse events during follow-up. Previous trials have shown that asymptomatic arrhythmias preceded these adverse events in a substantial proportion of patients. Ambulatory remote monitoring may allow early detection of electrocardiographic alterations with therapeutic and prognostic implications.
View Article and Find Full Text PDFJ Geriatr Cardiol
July 2025
Structural Heart and Interventional Cardiology, University of Arizona School of Medicine, DHMG Cardiology- Chandler, Chandler, USA.
Background: Transcatheter left atrial appendage occlusion (LAAO) has become a suitable alternative to anticoagulation in patients with atrial fibrillation (AF). However, outcomes among patients age > 75 years undergoing LAAO are lacking.
Methods: We included 723 consecutive patients with AF undergoing LAAO from August 2015 to March 2020.
JAMA
August 2025
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Importance: Data from randomized clinical trials on a long-term anticoagulation strategy for patients after catheter-based ablation for atrial fibrillation (AF) are lacking.
Objective: To evaluate whether discontinuing oral anticoagulant therapy provides superior clinical outcomes compared with continuing oral anticoagulant therapy in patients without documented atrial arrhythmia recurrence after catheter ablation for AF.
Design, Setting, And Participants: A randomized clinical trial including 840 adult patients (aged 19-80 years) who were enrolled and randomized from July 28, 2020, to March 9, 2023, at 18 hospitals in South Korea.